Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs United States Oil ETF (USO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs United States Oil ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B), while United States Oil ETF trades at $154.72 (market cap $1.86B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 4× United States Oil ETF's market cap, and United States Oil ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and United States Oil ETF for 21 Days on average.
| SYRE | USO | |
|---|---|---|
Market Cap | $7.35B | $1.86B |
Volume | 1,624,631 | 2,900,350 |
Sector | Health | — |
52-Week High | $108.92 | $161.86 |
52-Week Low | $22.18 | $66.17 |
Typical Hold Time | 0 Days | 21 Days |
Enterprise Value | $6.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
USO is trading at $153.09, up 1.36% with a bullish technical outlook supported by strong moving average signals. Recent news highlights ongoing Middle East tensions affecting oil supply chains, with OPEC+ maintaining steady output targets while G-7 nations plan strategic fuel releases to curb prices. The stock shows positive momentum despite mixed oscillators and geopolitical uncertainties.
The outlook remains cautiously optimistic with technical strength offset by fundamental data gaps and geopolitical risks. Investment opportunity exists if supply disruptions persist, but volatility from political events and coordinated government interventions pose significant near-term risks for energy sector investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About United States Oil ETF
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →
